Based in Essen, Germany, Brenntag Specialties, a global specialist in the distribution of chemicals and ingredients, has announced the signing of a strategic partnership with German startup Cambrium, an innovative biotech company that uses artificial intelligence (AI) and biology to design new, high-performance active ingredients.
This collaboration introduces NovaColl, a micromolecular plant collagen and 100 skin-identical %, to the beauty and personal care sector in the UK and Ireland, the Iberian Peninsula, France and Italy.
NovaColl is produced by precision fermentation, resulting in a vegan, cruelty-free and sustainable product. Its micro-molecular structure delivers powerful effects through the skin's layers, making it suitable for a wide range of skincare applications. By incorporating NovaColl into their formulations, brands can offer consumers a scientifically advanced solution that supports the skin's natural structure, promoting a younger, more radiant appearance.
At the Cosmet'Agora trade show in Paris on January 14 and 15, Brenntag will be presenting NovaColl on stand 111-112, where visitors and customers can find out more about this innovative ingredient.
"This innovative ingredient meets growing consumer demand for long-lasting, effective skincare solutions. Our Beauty & Care innovation and application centers across Europe are ready to assist customers with custom formulations including NovaColl, and our experienced technical service managers are committed to addressing individual needs and questions regarding vegan collagen. We plan to explore further opportunities with Cambrium to bring innovative products to market."said Patrick Koch, Beauty & Care Europe Sales Director at Brenntag Specialties.
Lucile Bonnin, PhD, Personal Care Manager at Cambrium, added: "It's amazing to see how the market has responded to our concept of AI-designed assets. We're thrilled to partner with Brenntag and its team of skilled technical experts to bring NovaColl and beyond to more innovators and formulations in the region. Partnerships like these are a great example of how we can turn molecular innovation into massive impact!"
